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Dendrobeaniamine A, a New Alkaloid from the Arctic Marine 
Bryozoan Dendrobeania murrayana  
Abstract: The new guanidine alkaloid Dendrobeaniamine A (1) was isolated 
from the organic extract of the Arctic marine bryozoan Dendrobeania 
murrayana. The chemical structure of 1 was elucidated by spectroscopic 
experiments, including 1D and 2D NMR and HRESIMS analysis. Compound 1 is 
a lipoamino acid, consisting of a C12 fatty acid anchored to the amino acid 
arginine. The bioactivity of 1 was evaluated using cellular and biochemical 
assays, but the compound did not show cytotoxic, antimicrobial, anti-
inflammatory or antioxidant activities 
Keywords: Arctic invertebrates; bryozoans; Dendrobeania murrayana; 
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1. Introduction  
Bryozoans are filter feeding, sessile invertebrates from which structurally diverse 
bioactive secondary metabolites have been isolated (Ryland 2005; Maltseva et al. 2017; 
Tian et al. 2018).  Despite this, the number of investigations into the natural product 
chemistry of marine bryozoans is still limited compared to other marine invertebrate 
phyla. To date, only around 220 secondary metabolites have been isolated from 38 
species of marine bryozoans (Blunt et al. 2018). These natural products include the 
flustramines (Peters et al. 2002), the eusynstyelamides (Tadesse et al. 2011), the 
bryostatins (Kollár et al. 2014) and the securamines (Hansen et al. 2017).  
As a part of our ongoing search for new secondary metabolites from Arctic 
invertebrates (Svenson 2013; Michael et al. 2017; Hansen et al. 2018), we are reporting 
a new secondary metabolite from the Arctic marine bryozoan Dendrobeania 
murrayana, from which the tetracyclic terpenoid murrayanolide have been previously 
isolated (Yu and Wright 1995). A detailed chemical analysis of the organic extract of D. 
murrayana using UHPLC-HRESIMS revealed the presence of an abundant compound 
not present in other bryozoan extracts analyzed by our research group. The compound 
was isolated and its structure elucidated using 1D and 2D NMR and HRESIMS 
analysis. Potential biological activities of the isolated compound was evaluated using 
cellular and biochemical assays. 
2. Results and discussion  
2.1. Extraction, dereplication and isolation of 1 
Specimens of Dendrobeania murrayana (550 g wet weight) were collected in the 
subtidal region of Vesterålsfjorden in Northern Norway and prepared into an organic 
extract (1.59 g). An aliquot of the organic extract was analyzed by UHPLC-HRESIMS. 
Comparison of base peak intensity (BPI) chromatograms of the organic extract from D. 
murrayana with other related bryozoans revealed the presence of a unique and 
prominent peak at Rt 5.7 min with an m/z of 369.2861 and a calculated elemental 
composition of C19H36N4O3. The elemental composition gave no hits when searched for 
in relevant databases (Dictionary of Marine Natural Products and ChemSpider). Based 
on the prominence of this peak (Figure S1) and its assumed novelty based on the 
database searches, we decided to isolate the compound and determine its structure.  
We isolated the compound from the organic extract using mass guided semi-preparative 
HPLC fractionation. In order to obtain sufficient purity of the compound, it was purified 
in two steps; first by applying a C18 column followed by a second step using a 
fluorophenyl column, both with gradients of water and acetonitrile as mobile phases. 
The isolation gave 2.5 mg of pure compound 1. 
2.2. Structure elucidation of 1 
Compound 1 was obtained as a golden yellow wax. The protonated compound had a m/z 
of 369.2861, and the elemental composition was C19H36N4O3. The IR spectrum of 
compound 1 had characteristic signals at 3279, 2936, 2363, 1726, 1626, 1544 cm−1, 
indicating the presence of amine, alkane, alcohol, carbonyl, alkene and imine groups, 
respectively. The UV λmax of compound 1 was 223 nm. Through a set of 1D (
1H, 13C) 
and 2D (1H, 13C, 15N) (HSQC, HMBC, COSY, NOESY, TOCSY, H2BC, 15N-HSQC 
and 15N-HMBC) NMR experiments, the structure of 1 could be determined (Figure 1, 
Table S1, Figures S2 and S4-S16). 
Initially, only 17 out of the 19 carbons could be identified in the 1D carbon spectrum, 
the missing carbons were later to be assigned C-15 (δC 55.0) and C-16 (δC 169.6). C-15 
was absent in HSQC, but could be identified in a (145 Hz) HMQC. Very weak peaks 
could eventually be confirmed in an optimized 1D carbon and HMBC. A fine splitting 
could  be observed for carbon peaks belonging to C-10 (δC 155.9), C-12 (δC 119.8), C-
13 (δC 168.7) and C-17 (δC 31.2). This indicates that there is a dynamic process, 
presumably C-15/C-16 rotamers. Comparison to the edited HSQC concluded the 
carbons to be in total 2 CH3, 11 CH2, 2 CH and 4 quaternary carbons. Of these, two had 
chemical shifts characteristic for carbonyls. The COSY and TOCSY data revealed one 
spin system consisting of H-14 (δH 7.40), H-15 (δH 4.32), H-17a (δH 1.87), H-17b (δH 
1.72), H2-18 (δH 1.63) and H2-19 (δH 3.21), H-20 (δH 7.55), and a second spin system 
consisting of an aliphatic chain H3-1 (δH 0.89) to H2-9 (δH 2.60). Arrangements of the 
aliphatic chain with respect to the other spin system and the connecting moiety were 
determined by HMBC, H2BC and COSY correlations (Figure S6-S8). The C-11 (δC 
24.8) methyl was attached to the quaternary C-10 (δC 155.9), based on HMBC 
correlations between H3-11 and C-9 (δC 33.9), C-10 and C-12 (δC 119.8) as well as 
between C-11 and H2-9 and H-12. The aliphatic chain was thus connected to C-10. C-13 
(δC 168.7) was identified as a carbonyl next to the aromatic C-12, again based on the 
HMBC pattern, including correlations from HN-14 (δH 7.40)and H-12 (δH 5.74).  
The other spin system presented some difficulty because of the putative C-15/C-16 
rotamers, resulting in the absence of long range through bonds correlations involving 
these carbons. The spin system itself was identified as the observable part of an 
arginine, and the side chain could be traced from the NH (HN-14) to the alpha- (C-15), 
beta- (C-17), gamma- (C-18) and delta carbon (C-19) and the epsilon NH (HN-20). The 
only experimental observation connecting it to the rest of the molecule was the 3JC13H14 
(Figure S6), supported by a NOE from H-14 to H-12 (Figure S10). In the H2BC 
spectrum, a coupling between H-20 (δH 7.55) and C-19 (δC 42.2) conformed the 
attachment of an NH to C-19. Furthermore, HMBC correlations between H2-19 (δH 
3.21) and C-21 (δC 158.7) linked the quaternary C-21 carbon atom to N-20 (δN 84.1). 
This placeed the remaining N2H3 atoms to C-21, forming a guanidine group. In order to 
strengthen that the arginine spin system is actually connected to the rest of the molecule 
via the N-terminal side and not via the C-terminal side, the nitrogen chemical shifts 
were extracted from a 15N-HSQC (Figure S13); δN20 84.1 and δN14 127.7 PPM. The 
nitrogen shifts were consistent with 1, but not with other potential structures (Figure 
S15 and S16). A weak 15N-HMBC between N-20 (δN 84.1) and H2-18 (δH 1.63) could 
be detected (Figure S14). 
The configuration around the C-10/C-12 double bond was determined considering the 
size of the 3JC11H12 and 
3JC9H12 couplings as estimated by CLIP-selHSQMBC and a 
selective SJS-scaled BIRD experiment (Figure S11 and S12). In both measurements, the 
3JC9H12 coupling was larger than the 
3JC11H12 coupling, which is consistent with a Z-
configuration of the double bond (i.e. the proton and the methyl in cis). This was 
confirmed by a clear NOE between H-12 (δH 5.74) and H3-11 (δH 1.84).  
 
2.3. Evaluation of the bioactivity of 1 
Compound 1 is structurally related to the synthetically produced and commercially 
available antimicrobial compound lauric arginate (2) (Ma et al. 2013) as well as the 
cytotoxic natural product spermidine 1 (3) (Schmitz et al. 1979) isolated from the soft 
coral Sinularia brongersmai (Figure S3). Compound 2 is active against both gram 
positive and gram negative bacteria, and against biofilm formation. Compound 3 is 
active against various cancer cell lines found in the National Cancer Institute 60-cell 
line panel at sub-µM concentrations. 
Amphipathic structures, consisting of a lipophilic chain and a charged region often act 
as surface-active molecules on biological membranes (Schreier et al. 2000; Schmidt and 
Wong 2013). Because of the structural features of 1 and its similarity to 2 and 3, the 
compound was tested for activity in a variety of bioactivity assays. Compound 1 was 
assayed against the cancer cell line A2058 and the non-malignant human lung 
fibroblasts cell line MRC-5, but displayed no effect at 10 µM. When evaluated for 
antimicrobial activity, 1 showed no activity at the highest assayed concentration (135.68 
µM) against S. aureus, E. coli, P. aeruginosa, E. faecalis or S. agalactiae (gr.B) and C. 
albicans, nor against the ability of S. epidermis to form biofilm. Furthermore, 1 was 
evaluated for its ability to inhibit the release of the cytokine tumor necrosis factor 
(TNFα) from the human acute leukemia monocyte cell line (THP-1) at 10 µM. 
Compound 1 did not show anti-inflammatory effect. Compound 1 was evaluated for its 
antioxidant effect at 135.68 µM µg using an oxygen radical absorbance capacity 
(ORAC) assay and no significant effect was observed. The bioactivities of the similar 
compounds 2 and 3 could thus not be found in 1.  
All the tree compounds share a C12 fatty acid chain, where 1 and 2 have a double bond 
between C-10 and C-12, and thus are monounsaturated. However, the stereochemistry 
around the double bond is different as 1 has cis while 3 has trans configuration. The 
presence of a double bond in 1 and 3 makes these structures more rigid compared to 2, 
which has an unsaturated fatty acid chain. Both compounds 1 and 2 contains the 
cationic amino acid residue arginine, but in 2 the hydroxyl group is ethylated so it can 
not be deprotonated and thus is not negatively charged. The zwitterionic nature of 1 
may result in ionic bond formation between the negatively charged hydroxyl oxygen 
and positively charged guanidine group, possibly preventing 1 from integrating with the 
negatively charged bacterial membranes. This may explain the lack of observed 
antibacterial activity of 1 despite its structural resemblance to 2. The spermidine part of 
3 differ from the polar amino acid groups of 1 and 2, as it lacks the terminal guanidine 
group, which is positively charged under physiological pH. Differences in observed 
bioactivities between 1 compared to 2 and 3 can thus be explained by presence and 
absence of specific substituents, differences in the overall three-dimensional structures 
of the compounds and possibly by an intramolecular ionic bond formation in 1. 
Reporting of natural products, despite being inactive in the selected bioassays, adds to 
the knowledge of the chemical diversity of invertebrate derived molecules. As 
production of secondary metabolites is energy consuming, the natural function of 1 is 
most likely to provide a beneficial effect for the producing animal, by acting as a 
pathogen or predator repellant, in competition for space of to protect against abiotic 
stress factors (Figuerola et al. 2017). Thus, it is likely that the compound is bioactive, 
just not in the bioactivity assays available to us (Li and Lou 2018). Future screening of 
1 in a wider selection of bioassays might reveal its biological function.   
2.4. Dendrobeaniamine A (1) 
Golden yellow substance; [α] 20 D -18.75±0.02 (c 0.16 MeOH); UV = (ACN) λmax 223 
nm; IR ν max 3279, 2936, 2363, 1726, 1626, 1544, cm
−1. 1H and 13C NMR data (see 
Table S1); HRMS m/z 369.2861 [M+H]+ (calculated for C19H37N4O3=369.2865).  
3. Conclusion 
Chemistry guided purification of the organic extract of the Arctic marine bryozoan D. 
murrayana yielded one new compound, Dendrobeaniamine A (1). This compound was 
present in abundant amounts in the organic extract. We were not able to pinpoint the 
activity of this compound by the bioactivity assays available to us. The bioactivity and 
natural function of this compound thus remains to be elucidated.  
 
Acknowledgements 
The authors would like to thank Marbank for marine bryozoan collection, identification, and 
extraction. We also would like to acknowledge the department engineers Marte Albrigtsen and 
Kirsti Helland for the bioactivity experiments.  
 
Supplemental materials 
Supplementary data: Materials and methods, Table S1, Figures S1–S16: HRESIMS 
chromatogram of the organic D. murrayana extract, key 2D NMR correlation, structural 
comparison of 1 – 3,  1H, 13C, HSQC+HMBC, H2BC, COSY, TOCSY, NOESY CLIP-
selHSQMBC and 15N NMR spectral data of isolated compound 1 associated with this article can 
be found online. 
 
Disclosure statement 




Blunt JW, Carroll AR, Copp BR, Davis RA, Keyzers RA, Prinsep MR. 2018. Marine 
natural products. Nat Prod Rep. 35(1):8-53. 
Figuerola B, Angulo-Preckler C, Nunez-Pons L, Moles J, Sala-Comorera L, Garcia-
Aljaro C, Blanch AR, Avila C. 2017. Experimental evidence of chemical defence 
mechanisms in Antarctic bryozoans. Mar Environ Res. 129:68-75. 
Hansen KO, Isaksson J, Bayer A, Johansen JA, Andersen JH, Hansen E. 2017. 
Securamine derivatives from the Arctic bryozoan Securiflustra securifrons. J Nat Prod. 
80(12):3276-3283. 
Hansen KO, Isaksson J, Glomsaker E, Andersen JH, Hansen E. 2018. Ponasterone A 
and F, ecdysteroids from the Arctic bryozoan Alcyonidium gelatinosum. Molecules. 
23(6). 
Kollár P, Rajchard J, Balounová Z, Pazourek J. 2014. Marine natural products: 
bryostatins in preclinical and clinical studies. Pharm Biol. 52(2):237-242. 
Li G, Lou H-X. 2018. Strategies to diversify natural products for drug discovery. Med 
Res Rev. 38(4):1255-1294. 
Ma Q, Davidson PM, Zhong Q. 2013. Antimicrobial properties of lauric arginate alone 
or in combination with essential oils in tryptic soy broth and 2% reduced fat milk. Int J 
Food Microbiol. 166(1):77-84. 
Maltseva AL, Kotenko ON, Kutyumov VA, Matvienko DA, Shavarda AL, Winson MK, 
Ostrovsky AN. 2017. Novel brominated metabolites from bryozoa: a functional 
analysis. Nat Prod Res. 31(16):1840-1848. 
Michael P, Hansen KO, Isaksson J, Andersen JH, Hansen E. 2017. A novel brominated 
alkaloid securidine A, isolated from the marine bryozoan Securiflustra securifrons. 
Molecules. 22(7). 
Peters L, Konig GM, Terlau H, Wright AD. 2002. Four new bromotryptamine 
derivatives from the marine bryozoan Flustra foliacea. J Nat Prod. 65(11):1633-1637. 
Ryland JS. 2005. Bryozoa: an introductory overview. 
Schmidt NW, Wong GCL. 2013. Antimicrobial peptides and induced membrane 
curvature: geometry, coordination chemistry, and molecular engineering. Curr opin 
solid st m. 17(4):151-163. 
Schmitz FJ, Hollenbeak KH, Prasad RS. 1979. Marine natural products: cytotoxic 
spermidine derivatives from the soft coral Sinularia brongersmai. Tetrahedron Lett. 
20(36):3387-3390. 
Schreier S, Malheiros SVP, de Paula E. 2000. Surface active drugs: self-association and 
interaction with membranes and surfactants. Physicochemical and biological aspects. 
Biochim Biophys Acta. 1508(1):210-234. 
Svenson J. 2013. MabCent: Arctic marine bioprospecting in Norway. Phytochem rev. 
12(3):567-578. 
Tadesse M, Tabudravu JN, Jaspars M, Strom MB, Hansen E, Andersen JH, Kristiansen 
PE, Haug T. 2011. The antibacterial ent-eusynstyelamide B and eusynstyelamides D, E, 
and F from the Arctic bryozoan Tegella cf. spitzbergensis. J Nat Prod. 74(4):837-841. 
Tian XR, Tang HF, Tian XL, Hu JJ, Huang LL, Gustafson KR. 2018. Review of 
bioactive secondary metabolites from marine bryozoans in the progress of new drugs 
discovery. Future Med Chem. 10(12):1497-1514. 
Yu CM, Wright JL. 1995. Murrayanolide, an unusual C21 tetracyclic terpenoid lactone 
from the marine bryozoan Dendrobeania murrayana. J Nat Prod. 58(12):1978-1982. 
 
 
 
 
 
 
 
